Standard BioTools Inc.

NasdaqGM:SLGC Stock Report

Market Cap: US$396.2m

Standard BioTools Balance Sheet Health

Financial Health criteria checks 6/6

Standard BioTools has a total shareholder equity of $496.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $565.0M and $68.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$453.81m
EquityUS$496.74m
Total liabilitiesUS$68.31m
Total assetsUS$565.05m

Recent financial health updates

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Jun 06
We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Dec 28
We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17
SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02
Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

SomaLogic appoints former Foundation Medicine chief as executive chair

Oct 17

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

Jul 26

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Jun 06
We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Apr 12

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

Mar 09
Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Dec 28
We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

Financial Position Analysis

Short Term Liabilities: SLGC's short term assets ($494.1M) exceed its short term liabilities ($27.8M).

Long Term Liabilities: SLGC's short term assets ($494.1M) exceed its long term liabilities ($40.5M).


Debt to Equity History and Analysis

Debt Level: SLGC is debt free.

Reducing Debt: SLGC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLGC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SLGC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 49.5% each year


Discover healthy companies